Señales en vivo de TRIL.TO | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 dic 1970 @ 19:00):

Stats
Volumen de hoy	60 423.00
Volumen promedio	127 472
Capitalización de mercado	0.00
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-34.06
ATR14	$0 (0.00%)

TRILLIUM THERAPEUTICS INC Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

TRILLIUM THERAPEUTICS INC Finanzas

Annual	2020
Ingresos:	$148 000
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.700

FY	2020
Ingresos:	$148 000
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.700

FY	2019
Ingresos:	$124 000
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-1.650

FY	2018
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-2.25

Financial Reports:

No articles found.

TRILLIUM THERAPEUTICS INC

Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622 that is in Phase I clinical trial of immunoglobulin G4 SIRPaFc protein; and TTI-10001, a small molecule stimulator of interferon genes agonist that senses cytosolic DNA for promoting tumor immunity, which is in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.